856677-05-9

Basic information

• Product Name: (5S)-N-[3-(4-BROMO-3-FLUOROPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHYL]ACETAMIDE
• Synonyms: (5S)-N-[3-(4-BROMO-3-FLUOROPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHYL]ACETAMIDE;(S)-N-((3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide;Acetamide, N-[[(5S)-3-(4-bromo-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-
• CAS NO: 856677-05-9
• Molecular Formula: C₁₂H₁₂BrFN₂O₃
• Molecular Weight: 331.14
• Product Categories: pharmacetical
• Mol File: 856677-05-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 504.277°C at 760 mmHg
• Flash Point: 258.778°C
• Appearance: /
• Density: 1.563g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5S)-N-[3-(4-BROMO-3-FLUOROPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHYL]ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (5S)-N-[3-(4-BROMO-3-FLUOROPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHYL]ACETAMIDE(856677-05-9)
• EPA Substance Registry System: (5S)-N-[3-(4-BROMO-3-FLUOROPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHYL]ACETAMIDE(856677-05-9)

Safety Data

• Hazardous Substances Data: 856677-05-9(Hazardous Substances Data)

Usage

General Description

"(5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide" is a chemical compound with the molecular formula C12H12BrFN2O3. It is a derivative of oxazolidinone and contains a bromine and fluorine atom on a phenyl ring. The compound has a chiral center at the 5th position, resulting in two enantiomers with the (5S) configuration being specified. The acetamide group is also present in the structure. (5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide may have potential applications in medicinal chemistry and drug development due to its structural features and potential biological activity. Further research and evaluation are needed to explore its pharmacological properties and potential uses in various fields.

InChI:InChI=1/C12H12BrFN2O3/c1-7(17)15-5-9-6-16(12(18)19-9)8-2-3-10(13)11(14)4-8/h2-4,9H,5-6H2,1H3,(H,15,17)/t9-/m0/s1

Upstream product

• 75-36-5 acetyl chloride 
• 856677-03-7 (S)-5-(aminomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 1032827-78-3 (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione 
• 396076-65-6 (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester 
• 183905-31-9 N-[(2S)-2-acetoxy-3-chloropropyl]acetamide 
• 1032827-77-2 2-((R)-3-(4-bromo-3-fluorophenylamino)-2-hydroxypropyl)isoindolin-1,3-dione 
• 856677-01-5 (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 108-24-7 acetic anhydride 
• 856676-99-8 methanesulfonic acid (5R)-3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl ester 
• 444335-16-4 (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxylmethyl)oxazolidin-2-one 
• 510729-01-8 (4-bromo-3-fluorophenyl)carbamic acid benzyl ester 
• 656-65-5 3-fluoro-4-bromophenylamine 

Downstream Products

• 843647-60-9 (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 1032827-76-1 N-(((S)-3-(4-(4-ethoxycarbonylphenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 877875-99-5 (5S)-N-[3-(4'-cyano-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 1401341-59-0 C₂₁H₂₁FN₆O₄ 
• 1401341-60-3 C₂₀H₂₁FN₆O₃*ClH 
• 1401341-61-4 C₂₁H₂₃FN₆O₃ 
• 1401341-63-6 C₂₄H₂₇FN₆O₅ 
• 1401341-64-7 C₂₂H₂₅FN₆O₄ 
• 1401341-65-8 C₂₃H₂₅FN₆O₃ 
• 1401341-66-9 C₂₃H₂₃FN₆O₃ 
• 1401341-67-0 C₂₆H₃₁FN₆O₅ 
• 1401341-69-2 C₂₂H₂₃FN₆O₅ 
• 1401341-70-5 C₂₄H₂₅FN₆O₆ 
• 1401341-71-6 C₂₆H₂₇FN₆O₈ 

Relevant articles and documents

OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.